share_log

常山药业(300255.SZ)发布2023年度业绩，由盈转亏至12.4亿元

Changshan Pharmaceutical (300255.SZ) announced its 2023 annual results, turning profit into loss to $1.24 billion

Zhitong Finance ·  Apr 28 17:29

Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan...

According to the Zhitong Finance App, Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan, a year-on-year decrease of 39.63%. The net loss attributable to shareholders of listed companies was $1.24 billion. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $1,258 billion. The basic loss per share was $1.35.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment